drugset / Trial / NCT00086177

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

NCT00086177

Phase 3 Completed 636 enrolled Juniper Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.

Timeline

Start
2004-04
Primary completion
2007-01
Completion
2009-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Progesterone Other / unclassified 90 mg Other

Indications